About clinically aggressive tumors, immunolabelling for STING was recorded in 24 of 32 neoplasms (75%), variably observed in primary tumors and metastatic lesions, with an H-score ranging from 10 to 250 (Fig. 2). Here, STING1 is linked to neoplasm.